Filter results

Clinical Studies

Open

  • The Vascular Glycocalyx: Measuring Blood Vessel Health in Non-Pregnant Women Rochester, Minn.

    This study will allow us to determine normal values for the health of this gel-like layer in non-pregnant women. We will also determine whether values vary from day to day, in the same person. Normal responses from this study will be compared with data obtained in other studies (for example, studies of women who had the pregnancy complication preeclampsia, or women who have other risk factors for heart disease). This will help us to determine whether the glycocalyx contributes to the risk of preeclampsia and heart disease in women with different risk factors.

Closed for Enrollment

  • Hypertensive Pregnancy Disorders and Future Coronary Artery Disease Rochester, Minn.

    The purpose of the study is to determine if:

    • A history of hypertensive pregnancy disorders (HPD), in general, and preeclampsia, in particular, compared to normotensive pregnancies, confers an increased risk for coronary artery disease (CAD) after controlling for traditional risk factors.
    • A history of HPD, in general, and preeclampsia, in particular, compared to normotensive pregnancies, is associated with more severe atherosclerotic disease at the time of the diagnosis of CAD.
    • A history of HPD, in general, and preeclampsia, in particular, compared to normotensive pregnancies, increases the risk for a composite outcome of subsequent CAD, atrial fibrillation, heart failure, stroke, and cardiovascular death in women with incident CAD.

  • Podocyturia in Diabetes Mellitus Type 2 and Proteinuric Glomerulonephritides Rochester, Minn.

    The goal of this study is to evaluate the presence of podocytes (special cells in the kidney that prevent protein loss) in the urine in patients with diabetes or glomerulonephritis (inflammation in the kidneys). Loss of podocyte in the urine may be an earlier sign of kidney injury (before protein loss) and the goal of this study is to evaluate the association between protein in the urine and podocytes in the urine.

  • Study of von Willebrand Factor Multimers in Preeclampsia Rochester, Minn.

    This study is being done to look for early indicators in the blood and urine of hypertensive disorders of pregnancy. Specifically, this study will look for differences between gestational hypertension, preeclampsia, HELLP syndrome and normal pregnancy. The following indicators will be studied: specific activated clotting factors (proteins in the blood that help form clots); the enzyme that cleaves clotting factor aggregates (clots); and microparticles (small particles shed from cells) from blood vessel cells, platelets (part of the blood that forms clots) and in the urine. Gestational hypertension refers to a benign form of high blood pressure in pregnancy.  The results of this study might lead to the development of methods to identify this condition early, and new ways to treat it

  • VEGF Signaling in Endothelial and Glomerular Epithelial Cells in Preeclampsia Rochester, Minn.

    This study is being done to compare factors that prevent formation of new blood vessels in pregnancy that may cause preeclampsia. We will measure changes in these factors in blood, urine, and placenta, including changes in genes, comparing normal pregnancy and pre-eclampsia. We will evaluate some of these factors in the abdominal fat, but these tests will be done only in women who will require Caesarean section for medical reasons. We may also compare these factors in pregnant versus non-pregnant/pre-menopausal woman.

  • Xolair (Omalizumab) for Treatment of Drug-induced Acute Tubulointerstitial Nephritis (AIN) Rochester, Minn.

    The investigators goal is to evaluate the role of XOLAIR® in treatment of Acute Tubulointerstitial Nephritis (AIN) with the goal of shortening the duration and dose of prednisone for treatment of drug-induced AIN. Currently there is no good treatment for drug-induced AIN. Prednisone is the standard treatment but is associated with many side-effects when used long-term and at high doses.

.